Xiufeng Wu

USPTO Granted Patents = 11 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 94(Granted Patents)

Company Filing History:

Eli Lilly and Company

patents

3 out of 1,271

The University of North Carolina at Chapel Hill

patents

where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11319370 - CD200R agonist antibodies and uses thereof (2022-05-03),

2. 10577415 - Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof (2020-03-03),

3. 10562982 - Methods for producing Fabs and bi-specific antibodies (2020-02-18),

4. 10294307 - Methods for producing fabs and bi-specific antibodies (2019-05-21),

5. 10047167 - Methods for producing fabs and bi-specific antibodies (2018-08-14),

6. 8892364 - Stabilized polypeptide compositions (2014-11-18),

7. 8603473 - Modified binding molecules comprising connecting peptides (2013-12-10),

8. 8084026 - Multispecific binding molecules comprising connecting peptides (2011-12-27),

9. 8021661 - Cripto binding molecules (2011-09-20),

10. 7960142 - Stabilized polypeptide compositions (2011-06-14),

11. 7951918 - Stabilized polypeptide compositions (2011-05-31),

Title: The Innovative Contributions of Xiufeng Wu

Introduction

Xiufeng Wu is a prominent inventor based in San Diego, CA, known for her significant contributions to the field of biotechnology. With a total of 11 patents, she has made remarkable strides in developing therapeutic solutions for various diseases.

Latest Patents

Among her latest patents are the CD200R agonist antibodies and their uses. This invention relates to anti-human CD200R agonist antibodies, which are aimed at treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergies, asthma, scleroderma, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), graft-versus-host disease (GvHD), and psoriasis. Another notable patent involves anti-CGRP/anti-IL-23 bispecific antibodies. These IgG bispecific antibodies bind to human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23), exhibiting high affinity and strong simultaneous neutralizing properties. They are particularly useful for treating various autoimmune diseases, including Crohn's Disease, Ulcerative Colitis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis, as well as alleviating pain associated with these conditions.

Career Highlights

Xiufeng Wu has worked with leading companies in the biotechnology sector, including Biogen Idec and Eli Lilly and Company. Her work has significantly impacted the development of innovative therapies that address complex health issues.

Collaborations

Throughout her career, Xiufeng has collaborated with notable professionals in her field, including Stephen John Demarest and Scott Glaser. These collaborations have further enhanced her research and development efforts.

Conclusion

Xiufeng Wu's innovative contributions to biotechnology and her extensive patent portfolio underscore her role as a leading inventor in the industry. Her work continues to pave the way for advancements in the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.